NCT05451056View on ClinicalTrials.gov

An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2026

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

sotorasib

Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity.

Trial Locations (1)

Unknown

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT05451056 - An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib | Biotech Hunter | Biotech Hunter